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E-mail address: s.alzabin@imperial.ac.uk (S. AlzabiThe development of an immune response to self antigens drives naive T cells to differentiate into
subsets of CD8+ and CD4+ effector cells including TH1, TH2, cells and the more recently described
TH17, and regulatory T cells (Treg). Rheumatoid arthritis is an autoimmune disease that engages
an uncontrolled inﬂux of inﬂammatory cells to the joints, eventually leading to joint damage. The
role that effector T cells play in the local or systemic maintenance of, or protection against, inﬂam-
mation and subsequent joint damage is now becoming better understood through the use of animal
models. In this review, we will explore the different animal models of RA, and their contribution to
elucidating the role that effector T cells play in the regulation, induction, and maintenance of
inﬂammatory joint disease. This understanding will aid in the design of more effective therapeutic
strategies for rheumatoid arthritis and other autoimmune disorders.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Rheumatoid arthritis (RA) is an immune-mediated disease that
is characterised by chronic inﬂammation in the joints and synovial
hyperplasia, leading to cartilage and bone loss. Earlier studies in
the joints of patients with RA identiﬁed the presence of T cells
(then characterised by formation of sheep erythrocyte rosettes)
in the synovium [1], while later studies have conﬁrmed this with
more speciﬁc tests which helped identify the T cell subsets that
are involved in disease. Both CD4+ and CD8+ cells have been char-
acterised in RA joints [2]. CD4+ cells that were isolated from the
joints of patients with RA and other inﬂammatory joint diseases
were less responsive to mitogenic stimulation in the presence of
interleukin-2 (IL-2) when compared to controls, whereas the re-
sponse of CD8+ cells did not differ. This suggested that joint-
resident CD4+ T cells are exhausted due to prior activation,
implicating them as potential effectors in RA [3].
The association of RA with HLA-DRB1 alleles encoding the
shared epitope provided the most compelling evidence for the cen-
tral role that CD4+ play in the pathogenesis of the disease. The fact
that MHC class II (MHCII) associations are also observed in animal
models of autoimmunity induced by immunisation with speciﬁc
antigens provides further support of a role for antigen speciﬁc
immunity in human disease. Animal models of RA provided an
unequivocal platform for dissecting the cellular and molecular im-cal Societies. Published by Elsevier
n).mune-mediated nature of inﬂammatory joint diseases. With the
aid of animal models, the role that CD4+ T cells play in disease
induction and pathogenesis was solidiﬁed using genetic modiﬁca-
tions in strains engineered to express a speciﬁc T cell receptor
(TCR) [4–6], as well as humanised models modiﬁed to express al-
leles of human MHCII that have been associated with RA [7–11].
On the other hand, the knockout or mutation of key T cell subsets,
the cytokines and/or signalling molecules they are associated with
[12,13], and the use of depleting or non-depleting antibodies (Ab)
[14–21], have allowed for a more speciﬁc understanding of the di-
rect contribution of certain factor(s) to disease initiation, mainte-
nance, or amelioration.
Pro- and anti-inﬂammatory cytokines and chemokines and/or
their receptors, key mediators of the effector function of T cells, ap-
pear to be centrally involved in the pathogenesis of RA [22]. It is
well established that in the presence of interferon-gamma (IFN-
c), local antigen-presenting cells (APCs) secrete interleukin-12
(IL-12) leading to the differentiation of CD4+ T cells into IFN-c-
secreting T helper type 1 (TH1) cells. In contrast, in the presence
of IL-4, CD4+ T cells transform into IL-4-, IL-5-, and IL-13-producing
TH2 cells. It was previously believed that TH1 cells were the princi-
pal mediators of pathology in autoimmune disease but this para-
digm was challenged with the ﬁndings that anti-IFN-c antibody
(Ab)-treated, IFN-c/ or IFN-cR/, or IL-12/mice develop colla-
gen-induced arthritis (CIA) and other classically categorized
TH1-mediated diseases such as experimental autoimmune enceph-
alomyelitis (EAE), a mouse model of multiple sclerosis (MS), in
some cases with more severity [23]. This paradox may beB.V. Open access under CC BY-NC-ND license.
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IL-17, namely TH17 cells, which have recently been characterised
in a number of inﬂammatory and autoimmune diseases such as
RA, multiple sclerosis and systemic lupus erythematosus [24–26].
A combination of transforming growth factor-beta1 (TGF-b1),
IL-6, and IL-23, leads to the differentiation and survival of TH17
cells. Because IL-23 shares the p40 subunit with IL-12, its discovery
was also instrumental in resolving the discrepancy that IL-12, a
TH1 promoting cytokine, is protective in inﬂammatory conditions
[27].
There are now a few well-characterised induced and spontane-
ous animal models of RA, each possessing some similarity to hu-
man disease. Spontaneous models are naturally more akin to
human RA, where the onset of disease and its cause is unknown,
whereas induced models provide a more controlled environment
with the ability to treat disease prophylactically; offering an exper-
imental system to develop vaccines that help prevent disease in
individuals genetically or environmentally predisposed to RA. Both
spontaneous and induced models present the opportunity to ex-
pand our knowledge of the aetiopathogenesis of RA and to evaluate
novel therapeutic strategies.
In this review, the contribution of effector T cells and cytokines
to the pathogenesis of RA will be dissected using knowledge gained
from induced and spontaneous animal models.2. CD4+ T cells
The presence of CD4+ in the synovium of patients with RA and
the strong association between RA and MHCII alleles is a reﬂection
of the signiﬁcant role that CD4+ T cells play in promoting and con-
trolling distinct aspects of disease pathogenesis [1,28]. Studies in
murine models of RA have shed light on the ability of CD4+ T cells
to initiate and maintain, or control disease via diverse mechanisms,
as detailed in the following sections.2.1. The role of CD4+ T cells in disease induction
CIA is a model of autoimmune inﬂammatory polyarthritis that
has clinical and pathological features of RA [29]. Also similar to
RA, susceptibility to CIA is associated with certain MHCII alleles
(H2-Aq and H2-Ar) [30] which make certain mouse strains more
susceptible. More importantly, this points to the contribution of
MHC-restricted CD4+T cells in development of disease [31].
Collagen-speciﬁc CD4+ T cells play an important role in the initia-
tion of the disease in immunised animals [14,32], and they are also
essential for the adoptive transfer of disease into SCID recipients
[17]. In addition, treatment of mice with either anti-TCR (CD3)
Ab [16] or anti-CD4 Ab [20] was shown to prevent disease. In con-
trast, a study using CIA in rats demonstrated that anti-TCR Ab
treatment does not affect disease [16], although this may have
been due to cross-linking and activation of the TCR, leading to its
downregulation, rather than its blockade. In earlier studies, CII-
reactive CD4+ T cells have been reported in some circumstances
to protect against CIA [33], and DBA/1 mice deﬁcient in CD4 were
still susceptible to CIA. This study suggested that, in the absence of
CD4+ T cells, CD8+ T cells and double-negative T cells play a role in
initiation of disease [13].
K/BN mice spontaneously develop a joint disorder with many
of the clinical, histological, and immunological features of RA in
humans [4,5]. This strain was generated by crossing the KRN/
C57Bl/6 TCR tg strain with NOD mice resulting, serendipitously,
in the generation of CD4+ T cells speciﬁc for the systemically dis-
tributed self-protein glucose-6-phosphate isomerase (GPI). This re-
sults in joint pathology due to the activation of GPI-speciﬁc B cells,
leading to the production of pathogenic autoantibodies that bind toarticular surfaces and recruit immune effector responses locally to
the joint [34]. It is of interest that GPI is not expressed speciﬁcally
in the joint but appears to localise at the cartilage surface and
thereby initiate joint inﬂammation [35]. Thus, the search for po-
tential autoantigens in human RA should not focus exclusively on
proteins expressed speciﬁcally in the joint.
The importance of CD4+ T cells in disease initiation is also
clearly highlighted in a series of studies using a rat model of RA,
the streptococcal cell wall (SCW)-induced arthritis in the Lewis
strain. In 1964, Pearson and Wood demonstrated that transfer of
spleen or lymph node cells from arthritic rats to healthy recipients
was able to cause disease [36]. In support of this, athymic rats are
resistant to disease, so were rats that have been injected with
cyclosporin A, a potent inhibitor of T cell proliferation and effector
cytokine production [37]. While these early studies highlighted the
importance of T cells in general in the establishment of disease, the
direct role of CD4+ T cells was conﬁrmed in a combination of char-
acterisation and depletion studies: In the ﬁrst study, the cells that
mediated disease transfer in the SCW model were identiﬁed as
cells lacking surface Ig and OX8 (rat CD8), but marked with the
W3/25 (rat CD4) antibody [38]. This was supported in a later study
that showed that depletion of CD4+ cells before the onset of disease
resulted in a very mild arthritis and relative resistance to subse-
quent SCW challenge [21].
The SKG mouse develops spontaneous arthritis which is attrib-
uted to a mutation in the ZAP-70 (f-associated protein of 70 kDa)
gene; this alters the threshold of T cell thymic selection leading
to autoimmunity [12]. Adoptive transfer studies in this model
showed that CD4+ T cells can mediate arthritis development in
the absence of antibody, although both the speciﬁcity of the TCR
and the peptide that they recognize in the context of disease is still
not identiﬁed. It was later discovered that SKGmice do not develop
arthritis when housed under speciﬁc pathogen-free (SPF) condi-
tions; however, injection of zymozan, a crude fungal b-glucan, lead
to the development of arthritis in SPF animals. This study high-
lighted that arthritis development in SKG mice is T cell mediated
but also depends on innate immune signals received from environ-
mental antigens such as fungi [39]. The role of CD4+ T cells in the
development of arthritis in SKG mice was also conﬁrmed using
non-depleting anti-CD4 mAbs, which were able to protect against
disease induction up to 60 days after treatment. Additionally, dis-
ease progression was retarded in arthritic SKG mice injected with
anti-CD4 mAbs [40]. FTY720 is a high-afﬁnity agonist for sphingo-
sine 1-phosphate receptors which exerts its immunomodulatory
effects by sequestration of lymphocytes within the thymus and
secondary lymphoid organs, therefore preventing them from recir-
culating to the periphery [41,42]. In b-glucan-induced arthritis,
development of disease in SKG mice was inhibited by FTY720
treatment because CD4+ T cells speciﬁcally accumulate in the thy-
mus and are prevented from access to joints and other peripheral
organs.
The spontaneous development of inﬂammatory joint disease in
mice with impaired TCR signalling challenges the commonly held
view that autoimmunity is the result of exuberant T cell responses.
Indeed, in a recent study, SKG mice were crossed to mice lacking
Src-like adapter protein (SLAP) to generate a progeny that is deﬁ-
cient in both ZAP-70 and SLAP signalling. Since SLAP is a negative
regulator of TCR, authors show that deﬁciency in SLAP in fact par-
tially restores thymocyte development in the absence of ZAP-70.
SLAP deﬁciency in SKG mice almost completely blocked zymo-
zan-induced arthritis. This was attributed to a rescue of TCR signal-
ling events, notably ZAP-70 phosporylation [43]. Possible
explanations for the development of autoimmunity in mice with
diminished TCR signalling include a failure to delete autoreactive
T cells in the thymus and a reduced level of Treg activity [44].
One possibility explored by Cope et al. is that the effects of
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hyporesponsiveness to TCR ligation leading to suppression of T
cell-driven immunoregulatory responses, while at the same time
promoting T cell survival and effector responses [45]. Indeed, a
single-nucleotide polymorphism in lymphoid tyrosine phospha-
tase, which is encoded by the PTPN22 gene and interacts with
ZAP-70 and other TCR proximal signaling molecules, is signiﬁ-
cantly associated with RA [46], supporting the notion that
disrupted TCR signalling confers susceptibility to RA.
Adjuvant-induced arthritis (AA) is a model of RA that is induced
by a single injection of complete Freund adjuvant (CFA) in to genet-
ically susceptible rat strains. Genetic predisposition involves MHCII
genes, clearly implicating the importance of the CD4 response in
disease initiation [47,48]. Transfer of AA into Dark Agouti (DA) rats
was induced by transfer of CD4+ but not CD8+ cells [49]. Addition-
ally, disease transfer occurs with Concavalin A activated lympho-
cytes isolated from the spleen or draining lymph nodes of
immunised rats [38], and by CD4+ T cell lines or clones cultured
with the mycobacterial antigens [50,51]. Although earlier studies
pointed to an association between immunity to heat shock pro-
teins and adjuvant arthritis [52], no single mycobacterial immuno-
gen has been shown to be responsible for the arthritogenic
response in this model [53]. It has been proposed that the induc-
tion of adjuvant arthritis is due to a mycobacterial cell wall compo-
nent, muramyl dipeptide, which is stimulatory for the innate
immune system without evoking a speciﬁc immune response
[54]. More recently, it has been shown that a number of adjuvants
lacking immunogenic properties cause arthritis in susceptible
strains of rats, including avridine [55], incomplete Freund’s adju-
vant and pristane [53]. One possible explanation for the induction
of arthritis following immunisation with adjuvants is that there is
an increase in the activity of APC [56], leading to the presentation
to autoreactive T cells of a hitherto unrecognised or ‘‘sequestered’’
endogenous antigen. The possibility that human RA could also be
initiated by exposure to environmental factors with adjuvant-like
activity has been highlighted by experiments in which arthritis
was found to be induced in susceptible DA rats by percutaneous
exposure of adjuvant oils [57], or even a mineral oil-containing
cosmetic product [58].
Proteoglycan-induced arthritis (PGIA) is a model of polyarthritis
induced by the injection of human cartilage proteoglycan plus
adjuvant intraperitoneally genetically susceptible mice (BALB/c
and C3H). Both T and B cells are required for disease induction, be-
cause depletion of either subset prevents arthritis. Upon adoptive
transfer, ex vivo depletion of CD4+ cells using anti-Lyt1.2 Ab re-
duces incidence by 75% [59]. Arthritis was completely blocked
when anti-CD4 antibodies were administered in vivo to immun-
ised mice [60].
In a more recently described model (TS1  HACII mice) the
spontaneous development of arthritis was examined in transgenic
mice that express a TCR speciﬁc for a nominal antigen (hemagglu-
tinin) as well as the same antigen under the MHC class II promoter
[61]. This leads to the activation of autoreactive CD4+ T cells, sys-
temic pro-inﬂammatory cytokine production and the spontaneous
development of arthritis. The signiﬁcance of these ﬁndings is that
autoreactive CD4+ T cells recognizing an antigen that is not joint
speciﬁc can induce arthritis and this may explain the failure to
identify a joint speciﬁc autoantigen in human RA.
2.2. The role of CD4+ T cells in disease maintenance
Different studies using the aforementioned animal models as
well other models place CD4+ T cells in centre stage by highlighting
their role in disease maintenance and joint destruction. In the SCW
model, depletion of CD4+ T cells after disease onset signiﬁcantly
ameliorated disease [21]. This sheds important light on the factthat CD4+ T cells are important in both disease initiation and main-
tenance in this model.
DBA/1 mice, which are susceptible to CIA, are also prone to
arthritis when injected with GPI [62], the antigen that drives
arthritis in the above mentioned K/BN model. Treatment of ar-
thritic DBA/1 mice in this model with depleting CD4 antibodies
was able to ameliorate established disease [62].
In AA Administration of anti-CD4 Ab to rats with established AA
ameliorated disease, but disease rebounded after withdrawal [18].
Antigen-induced arthritis (AIA) is a model of inﬂammatory arthri-
tis which is induced by the intraarticular injection of methylated
bovine serum albumin (mBSA). Injection of mice with anti-CD4
Ab was able to ablate established AIA but not CIA [16]. In agree-
ment with this, while anti-CD4 Ab administration is therapeutic
throughout the course of AA, its effects seem to be more pro-
nounced in the acute (day 3) rather than the chronic (day 21)
stages [63]. In contrast, blockade of CD4 is less effective in control-
ling acute and early chronic AIA when compared to its ability to
diminish late chronic AIA [64]. Thus, the role of CD4+ T cells in dis-
ease maintenance is likely to depend on the particular model, and
on the stage of disease. More importantly, CD4 blockade will also
eliminate Treg cells, which are believed to be key suppressors of
disease. A detailed discussion of the role of this effector cell will
be discussed in Section 2.4.
2.3. TH1 cells
2.3.1. Interferon-c
Earlier studies failed to detect high levels of T cell derived cyto-
kines in the synovium of patients with RA although they did doc-
ument the presence of CD4+ T cells and IFN-c which supported
the hypothesis that it is in fact a TH1-driven disease [2,65,66]. More
importantly, later reports conﬁrmed the presence of IFN-c-
secreting CD4+ T cells in the synovium of patients with RA with
the use of ﬂorescence activated cell sorting (FACS) or a combina-
tion of FACS and RT-PCR techniques [67–69].
Mouse models of RA were very useful in appreciating the para-
doxical signiﬁcance of TH1 cells in the pathogenesis of RA. Interest-
ingly, a few studies using knockout mice or neutralising antibodies
have challenged the originally pathogenic role of IFN-c [70,71] by
shedding light on the protective role for IFN-c in RA. In the CIA
model, neutralization of IFN-c accelerated the course of CIA and
was associated with increased IL-17 levels in the serum and joints
of arthritic animals [72]. Administration of recombinant IFN-c pro-
tects rats from SCW-induced arthritis because of its ability to inhi-
bit leukocyte recruitment to the joints, the production of
prostaglandin E2 (PGE2) and the proliferation of synovial cells
[73,74]. In agreement with these ﬁndings, IFN-c/ mice induced
with AIA have exacerbated disease which was reversed by intraar-
ticular injection of recombinant IFN-c [75].
In a recent study, Frey et al. have demonstrated that mice genet-
ically lacking IFN-cR show exacerbated CIA [71,76]. Conversely, the
latter study also shows that G6PI-induced arthritis is reduced in
IFN-cR/ mice and hypothesised that the role of IFN-c in disease
may be affected by the presence of an adjuvant.
The study by Frey et al. [76], showing lower susceptibility to
GPI-induced arthritis, along with a few others, supported the origi-
nal hypothesis of a pathogenic role for IFN-c. Genetic deletion or
neutralisation of IFN-c results in signiﬁcantly reduced PGIA. Con-
versely, the injection of recombinant IFN-c into the hind paws of
DBA/1 mice before CIA onset results in a more severe disease and
with higher incidence [52]. Also, in the genetically susceptible
DBA/1 mice, the induction of spontaneous arthritis is shown to re-
quire endogenous IFN-c because IFN-cR/ mice are less suscepti-
ble to spontaneous disease [77]. A separate study also showed that
IFN-cR/ mice are less susceptible to CIA [78]. This is also
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immunisation in the draining lymph nodes of CIA mice [79], and
by the predominance of TH1 cells in the pre-arthritic stage of CIA,
but not later in disease [32,80]. Additionally, neutralisation of
IFN-c in the pre-onset or early stages of CIA was able to protect
against disease whereas late administration of IFN-cmAbs exacer-
bates it [81].
It is important to keep in mind that CD8+ T cells are key produc-
ers of IFN-c. In a later section, the equally paradoxical role of CD8+
T cells in RA will be discussed. Therefore, the aforementioned stud-
ies could be a reﬂection of the role that CD8+IFN-c+ T cells, also
known as cytotoxic T cells (Tc), play in the pathogenesis of RA.
Regardless, there is evidence that prophylactic depletion of CD4+
T cells, which prevents the development or transfer of CIA, results
in a clear reduction of IFN-c in the draining lymph nodes of mice
[20]. This implicates CD4+ T cells as the major producers of IFN-c
in the CIA model and agrees with the ﬁndings that IFN-c is impor-
tant in the initial stages of disease, or for its induction.2.3.2. Interleukin 12
IL-12 is composed of two subunits, p35 and p40, the latter is
shared with IL-23. IL-12 and IL-23 also share IL-12Rb1, whereas
IL-12Rb2 is speciﬁc to IL-12. Until 2000 when IL-23 was discovered
[82], many of the gene targeted studies using IL-12 knockout mice
should be interpreted with caution as the original knockout mouse
targets the p40 subunit, and therefore reﬂects a double deﬁciency
in both IL-12 and IL-23. Additionally, since these two cytokines
regulate TH1 and TH17 responses, respectively, the contribution
of IL-12 to the regulation or as a reﬂection of Th1 responses in
RA should also be revisited using antibodies that speciﬁcally target
IL-12 through the p35 subunit. In fact, studies using IL-12/23p40/
, IL-12p35/ or IL-23p19/mice were instrumental in challeng-
ing the concept that autoimmune diseases such as MS, IBD and RA
are TH1-mediated [83–85].
Using the CIA model, Murphy et al. clearly demonstrated that
speciﬁc genetic ablation of IL-12p35 exacerbates disease [85]. This
is consistent with reports showing that IFN-c in CIA is protective,
thus suggesting that the presence of TH1 cells during disease may
in fact be beneﬁcial in controlling disease. Earlier studies have sup-
ported this: The administration of high doses of IL-12 during CIA is
able to ameliorate disease [86]. In contrast to its seemingly protec-
tive role in CIA, IL-12p35/p40 heterodimer gene transfer exacer-
bates arthritis in the SCW model [87].
A recent study using IL-12p35/ or IL-12Rb2/ in the K/BN
serum transfer model have opposed ﬁndings of the above studies.
Both genetic depletions were refractory to disease and correlated
with lower levels of IL-6, IL-4 and IFN-c but higher levels of
TGF-b. Administration of IL-12 restored joint inﬂammation
and suppressed TGF-b. The differences in this model may be
explained by the fact that it is an antibody-mediated rather than
a T cell dependent model [27]. The contribution of IL-12 and its
receptor to disease development, however, was attributed to the
prevalence of NKT cells expressing high levels of IL-12Rb in the
inﬂamed joint.2.4. TH17 cells
2.4.1. Interleukin 17
The role of IL-17 in the pathogenesis of arthritis was ﬁrst con-
ﬁrmed in the CIA model. Messenger RNA levels of IL-17 in the
joints of immunised mice increased as disease progressed, and
when IL-17 was blocked using soluble IL-17 receptor-Fc, disease
was suppressed in a dose-dependent manner, while systemic and
local adenoviral gene transfer of IL-17 exacerbated disease pro-
gression and joint damage [88]. The same study also supported arole of IL-17 in the SCW model by showing that over-expression
of IL-17 results in a more chronic and erosive arthritis. The IL-17
family constitutes six identiﬁed members: IL-17A–F. The expres-
sion of each of the family members and their contribution to dis-
ease pathogenesis was recently described in the CIA model [89].
The expression of IL-17A, IL-17B, IL-17C, and IL-17F, and their
receptors were found to be up-regulated in the joints of arthritic
mice compared with controls. IL-17A and IL-17F were only ex-
pressed in the CD4+ population, IL-17B was expressed in the carti-
lage, and IL-17C was expressed by CD4+ cells as well as myeloid
cells. Adoptive transfer of CD4+ T cells over-expressing IL-17B
and IL-17C exacerbated disease. Blockade of IL-17B signiﬁcantly re-
duced disease progression and bone destruction. This study
conﬁrmed that not only IL-17A, as previously reported, but also
IL-17B and IL-17C play a signiﬁcant role in the pathogenesis of
arthritis in the CIA model [89].
The role of IL-17 in CIA was also investigated using IL-17A/
mice. Nakae et al. demonstrated that disease severity and inci-
dence was markedly decreased in mice genetically lacking IL-
17A, and that the presence of IL-17A was necessary for the priming
of collagen-speciﬁc T cells and for IgG2a production. Intriguingly,
disease was not completely abolished, suggesting that factors other
than IL-17/TH17 contribute to pathogenesis in the CIA model [90].
It is also possible that other IL-17 family members, which have
been shown to also contribute to disease in the CIA model [89],
compensate for the lack of IL-17A. In a separate study, the same
group reported that the lymph nodes of IL-1 receptor antagonist-
deﬁcient mice (IL-1Ra/), which develop a spontaneous and
destructive arthritis due to unchecked IL-1 signalling, express IL-
17 30-folds higher than control wild type mice. When IL-17/
were crossed to IL-1Ra/ mice, the development of arthritis was
completely suppressed [91]. The latter study clearly demonstrated
that the IL-1-dependent spontaneous development of arthritis is
due to the ability of IL-1 signalling to generate a pathogenic pool
of TH17 cells. However, consistent with previous reports, the con-
tribution of IL-1 in the induction of IL-17/TH17 is not direct but acts
through IL-1-induced OX-40 [88].
Zymozan- or b-glucan-induced arthritis in the SKG model was
also found to involve CD4+IL-17+ T cells. Genetic ablation of IL-17
in the SKG mouse completely blocked transfer of arthritis to
Rag2/ recipient mice. IL-17 production by activated CD4+ T cells
was not detected in IL-6/ SKG mice, whereas the numbers of
CD4+IL-17+ T cells from the DLN of TNF-a/, IL-1b/ or IFN-c/
SKG mice were comparable to those in control mice. The transfer
of cells from IL-6/ SKG to Rag/IL-6+/+ mice restored IL-17 pro-
duction by CD4+ T cells. This study suggested that arthritis in SKG
mice is TH17-dependent and relies on IL-6 for the development of
this pathogenic population [92]. Non-depleting anti-CD4 Ab
administration, as discussed above, protected mice from disease
development. This was found to be due to a decrease in TH17 cells
and the mRNA levels of IL-17 in the joints and draining lymph
nodes of arthritic SKG animals [40].
Also in the CIA model, antibody blockade of IL-17 after disease
onset was able to signiﬁcantly reduce disease progression and joint
damage. Blockade of IL-17 was also moderately effective in mice
that have a more severe arthritis [93]. In a mouse model of inﬂam-
matory arthritis, which is a version AIA, mBSA is injected into the
knee joint, followed by 3 daily subcutaneous injections of IL-1b.
Mice rapidly develop an acute monarthritis in the injected knee
joint, which peaks 7 days after the initial mBSA injection and typ-
ically resolves by day 21. Join inﬂammation correlated with an in-
crease in TH17 cells in the affected joint, and anti IL-17 Ab
administration signiﬁcantly reduces disease severity [94].
The K/BN cell transfer model (KRN-CTM) is a recent model of
chronic arthritis where spleen cells from a K/BN donor are trans-
ferred into a T cell deﬁcient B6.TCR.Ca/.H-2b/g7 recipient. This
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disease pathology. All mice receiving K/BN spleen cells polarised
in TH17 conditions developed arthritis, and this cell population ex-
pressed both IL-17 and IFN-c. Neutralization of IFN-c on the day of
cell transfer after TH17 polarisation accelerated disease onset and
severity [95], consistent with the regulatory role of IFN-c described
in the previous section.
Antibody blockade of the IL-17 receptor using an IgG1 fusion
protein, or using mice deﬁcient in IL-17RA was also effective in
ameliorating joint damage in AIA [96]. In the SCW model, IL-17R
deﬁciency had no effect after a single injection of SCW fragments.
However, joint inﬂammation and damage was signiﬁcantly re-
duced after repeated SCW injections, and correlated with reduced
IL-1b, and metalloproteinases 3, 9 and 13. This study deﬁnes a role
for IL-17R signalling in driving a more chronic, rather than acute,
arthritis [97]. Very little is known about how other IL-17R family
members contribute to joint disease in animal models. However,
in RA synovium, the expression of IL-17RA, B, C and D were all de-
tected in comparable levels [98].
While most models support the involvement of TH17 cells in the
pathogenesis of arthritis, the PGIA model challenged these ﬁnd-
ings. In mice genetically deﬁcient in IL-17, the onset, clinical and
histological parameters of arthritis was equivalent to wild type
controls [99]. Interestingly, PGIA switches to an IL-17-dependent
model in the absence of IFN-c. IFN-c/mice have a delayed onset
of PGIA and a 10-fold increase in IL-17 compared to wild type mice,
and crossing IFNc/ to IL-17/mice results in a signiﬁcant reduc-
tion in disease severity and a delay in disease onset [100]. These
ﬁndings suggest that the involvement of IL-17/TH17 in PGIA path-
ogenesis is dependent on IFN-c.
2.4.2. Interleukin 23
The role of IL-23 in the induction/development of TH17 cells
was ﬁrst established in the EAE model of MS [101]. IL-23 was able
to induce the speciﬁc production of IL-17, IL-6, TNF-a, and integrin
a-3 from CD4+ cells, when compared to IL-12 stimulation which
preferentially induced a separate set of genes such as IFN-c,
CCL5, and TRAIL. IL-6 synergises with IL-23 to promote TH17 devel-
opment through the induction of IL-23R on TH17 cells [102].
Intriguingly, IL-23R is also induced by the TH1 transcription factor
T-bet [103]. Conversely, IL-23 is shown to inhibit T-bet and Foxp3,
the transcription factor associated with Treg cells, in draining LNC
from CIA animals. However, IL-23-driven induction of IL-17A and
F is defective in T-bet/ mice [104]. In RA patients, some allelic
variants or haplogroups of IL-23R are shown to represent indepen-
dent risk factors for rheumatoid arthritis [105].
IL-23p19/mice are resistant to CIA, this correlated with a de-
crease in TH17 but not TH1 cells [85]. This is consistent with the
observation that IL-12 deﬁcient p35/ mice, which develop a
more severe arthritis, have more CD4+IL-17+ cells in the draining
lymph nodes and higher mRNA levels of IL-17, IL-1b, TNF-a and
IL-6, cytokines associated with TH17 cells, in their joints. Mice engi-
neered to over-express IL-15 show exacerbated CIA that correlated
with an increase in TH17 cells. This is due to the ability of IL-15 to
induce IL-23R in the draining lymph nodes. IL-15 also synergised
with IL-23 to induce collagen-speciﬁc IL-17 production [106].
Additionally, the over-expression of transcription factor suppres-
sor of cytokine signalling-3 (SOCS-3) [107], which is a negative reg-
ulator of IL-23-induced IL-17 production, is protective in the CIA
model. This correlated with a ﬁvefold decrease in mRNA levels of
IL-23 as well as a threefold decrease in protein levels, and a damp-
ened TH17 response [108]. In contrast to the CIA model, IL-23p19/
 mice were not refractory to AIA as the lack of IL-23 did prevent
disease progressing to a destructive state [109], although it did
lead to a reduction in CD4+ cells expressing both IL-17A and F.
TH1 cells were unchanged when compared to control animals.2.5. Regulatory T cells
It is now well-established that CD4+CD25+ Foxp3+ (Treg) cells
play a critical role in the prevention of autoimmunity. Mice and
humans lacking the key transcription factor for Treg, forkhead box
protein 3 (Foxp3), develop multi-organ autoimmune disease [110].
Studies in a fewmodels have indicated that CD4+CD25+ Treg cells
are capable of modifying disease, and the role of Treg cells has been
most extensively studied in the CIA and K/BN arthritis models. In
CIA, Treg cells can be found in the joints, synovial ﬂuid and draining
lymph nodes of arthritic mice [111,112]. However, while Treg cells
from healthy mice or mice that have responded to treatment are
effective in suppressing effector T cell responses, those from dis-
eased animals are not [111]. Additionally, several studies in knock-
out mice or in mice treated with effective disease-ameliorating
therapies associate disease resistance or improvement with an in-
crease in Treg numbers in the DLN and joints of arthritic mice or an
enhancement in Treg suppressor activity [111,113–116]. On the
other hand, disease-exacerbating genetic deletions or therapies re-
sult in decreased Treg numbers or activity [108,117]. Adoptive trans-
fer of CD4+CD25+ cells to arthritic animals is able to retard disease
progression and collagen-speciﬁc T and B cell responses [112], and
CD25+ depletion before immunisation exacerbated disease onset
[118]. Kelchtermans et al. reported that the exacerbated CIA in
IFN-cR/mice is, in part, due to decreased Treg suppressive function
in the absence of IFN-c signalling [119].
Depletion of CD4 in the SKG model is able to control disease
both prophylactically and after onset as mentioned above [40].
The number and activity of Treg is decreased in SKG mice [44],
and protection from disease after anti-CD4 mAb treatment was
associated with an increase in Treg cells and a decrease in TH17
cells. Interestingly, ex vivo TH17-polarizing conditions favoured
Treg generation in treated but not arthritic mice [40], thus shifting
the balance in favour of protection under seemingly pathogenic
conditions. High-avidity TCR–peptide interactions increase thymic
Treg numbers, supporting a role for TCR signal strength in Treg
development [120,121].
In the GPI-induced model, arthritis resolves around 3 weeks
post immunisation. Expectantly, depletion of Tregs using anti-
CD25 mAb resulted in disease being sustained up to 12 weeks post
immunisation [122]. Similarly, depletion of CD25 before immuni-
sation with mBSA in the AIA model resulted in higher antigen-
speciﬁc responses and a more exacerbated disease which was
ameliorated after CD4+CD25+ cell transfer [123].
It was interesting to observe that the numbers of Treg cells in ar-
thritic TS1  HACII mice were three times higher than those in
controls. Treg cells from transgenic animals were equally suppres-
sive, but integuingly, these Treg cells expressed lower levels of
the clonotypic TCR and are therefore not antigen-speciﬁc. This
indicates that disease development in TS1  HACII mice despite
the higher frequency of Treg cells is possible because there are less
antigen-speciﬁc Treg cells [61].
NOD-Foxp3sf mice carry a mutation in the foxp3 gene and de-
velop multi-organ autoimmune disease [124]. Crossing KRN mice
with NOD-Foxp3sf facilitated a system in which the lack of Treg cells
inﬂuences disease in the K/BN model. KRN mice lacking func-
tional foxp3 have a more aggressive arthritis which is character-
ised by faster disease progression and more severe joint
destruction [125,126]. In an elegant study using KRN mice geneti-
cally engineered to express foxp3 under a GFP promoter, Monte
et al. demonstrated that Treg cells from arthritic animals, unlike
anergic control Treg cells from healthy animals, are able to prolifer-
ate but are also more susceptible to apoptosis [55]. This proposed a
mechanism by which Tregs, during disease, fail to suppress patho-
genic responses due to their inability to survive as much as those
from a healthy animal.
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the aetiopathogenesis of autoimmune diseases like RA, there is evi-
dence of compromised Treg activity in human disease as well as in
animal models. For example, research carried out by Ehrenstein
et al. showed that CD4+CD25+ Treg derived from RA patients, unlike
those from healthy donors, were unable to modulate pro-inﬂam-
matory cytokine production by T cells stimulated with anti-CD3
or monocytes stimulated with LPS [127]. However, following treat-
ment with anti TNF-a mAb there was an increase in the ability of
CD4+CD25+ T cells to inhibit cytokine production and to confer
suppressive properties to effector T cells. Another important obser-
vation was that TNF-a blockade led to an increase in numbers of
circulating regulatory T cells in RA patients and it was concluded
from this study that the activity of regulatory T cells is diminished
in RA and that TNF-a blockade increases the numbers and the
activity of CD4+CD25+ T cells. More recent studies conﬁrmed that
TNF-a blockade in RA leads to the emergence of a foxp3+ Treg cell
population that mediates suppression via TGFb and IL-10 [128].
In another study, increased spontaneous apoptosis of
CD4+CD25+ T cells was demonstrated in patients with active RA
and this was reduced by treatment with TNF-a blocking mAb
[129]. Similarly, evidence was reported that CD4+CD25+ T cell sup-
pressor function is compromised in RA by myeloid cell-derived
inﬂammatory mediators [130]. More recently it was conﬁrmed
that suppressor cell function of Treg cells is defective in RA and that
this correlates with reduced foxP3 expression [131]. Both defects
could be reversed by TNF-a blockade [131]. Treg function has also
been shown to be defective in collagen-induced arthritis (CIA)
[119] and there is also evidence from other diseases that TNF-a
compromises the activity and/or numbers of Treg cells. For exam-
ple, deﬁcient suppressor cell activity was observed in human
CD4+CD25+ Treg in allergic asthma and this deﬁciency could be cor-
rected by TNF-a blockade [132]. Similar conclusions were reached
in EAE [133], MS [134] and type 1 diabetes [135]. Thus, there is
abundant evidence that inﬂammatory mediators, such as TNF-a,
inﬂuence Treg activity.
2.6. TH2 cells2.6.1. Interleukin-4
In established early RA predominance of TH2 cytokines is
thought to contribute to disease initiation [22]. Mice predisposed
to TH2 cytokines (BALB/c and STAT4-deﬁcient mice) developed a
more severe arthritis than mice biased towards TH1 cytokines
(C57BL/6 and STAT6-deﬁcient mice). However, other studies have
revealed a predominance of TH2 cells in established arthritis
[32,80].
IL-4 is a cytokine that is produced by activated T cells, mast
cells, NK T cells, eosinophils and basophils. It functions to direct
the differentiation of TH2 cells, suppress IFNc and TH1, and pro-
mote B cell class switching to the IgG and IgE isotypes.
Several studies using the CIA model have described a protective
role for IL-4 [20,72,136–138]. Administration of IL-4 prophylacti-
cally or after onset was able to delay the onset of CIA and reduce
clinical parameters [137,138], and overexpression of IL-4 by aden-
oviral infection systemically or into arthritic joints, or by the intra-
peritoneal injection of cells engineered to secrete IL-4, is
moderately effective in reducing bone erosion and joint damage,
and in halting the progression of CIA [136,139–141]. The protective
effect of IL-4 is improved in combination with IL-10 [142,143].
Additionally, DCs or APCs genetically engineered to over-express
IL-4 are also able to suppress CIA and/or IL-17 production [144–
147]. Administration of IL-4 during PGIA is also able to reduce dis-
ease [148]. On the other hand, blockade of IL-4 using mAbs was
able to control CIA progression in some cases [72], while in othersit has no effect [149]. Genetic deletion of IL-4 exacerbates PGIA
[150]. Most of the studies involving amelioration of arthritis with
IL-4 correlated this with a reduced the level of anti-CII antibody
production [137,138,147], and in PGIA, there is a sixfold increase
in proteoglycan-speciﬁc IgG2a autoantibodies. These studies sug-
gest that IL-4 may ameliorate disease by affecting antigen-speciﬁc
autoantibody synthesis.
While most studies describe a protective role for IL-4 in CIA,
there is also evidence that blockade of IL-4 is effective in control-
ling CIA. Prophylactic treatment with IL-4 mAbs was able to signif-
icantly reduce the incidence and clinical score [151]. Interestingly,
IL-4/ mice were only protected from CIA when immunised with
collagen in incomplete Freund’s adjuvant. The immunisation with
CFA resulted in IL-4/ animals with a chronic-relapsing CIA com-
pared to the acute disease seen in controls [152].
While the K/BN model is predominantly antibody-mediated,
there is a clear involvement of CD4+ T cells expressing a GPI-
speciﬁc transgenic TCR as aforementioned. This model is not char-
acterised as a TH2 disease, but Ohmura et al. have shown that IL-4,
produced by CD4+ T cells, is important in the development of dis-
ease, but that the cytokine proﬁle of arthritic mice does not reﬂect
a TH2 response. It may be that IL-4 in this system is needed for
mounting a pathogenic antibody response [153].
IL-4 seems to play a role in the maintenance of tolerance. Toler-
ance to CII can be induced by the oral administration of CII or the
injectionof CII-treated splenocytes; andblockadeof IL-4usingmAbs
or IL-4/mice reverses tolerance to CIA [154,155]. Similar to the ef-
fect of IL-4 blockade in the CIA model, IL-4 mAbs also diminish tol-
erance induced after intranasal injection of mBSA in the AIA model
[156]. The same group also reported that prophylactic treatment
with anti-IL-4 mAbs results in a more severe AIA [156].
Analysis of the levels of IFN-c and IL-4 in the synovial ﬂuid and
serum of RA patients, indicate that TH1 activity was clearly pre-
dominant over TH2 activity when compared with healthy subjects.
Additionally, under TH2-mediated conditions such as atopic disor-
ders and during pregnancy, RA symptoms seem to improve
[157,158]. There is evidence that the increase of estrogen during
pregnancy leads to TH2 polarization and systemic IL-4 production;
therefore the prevalence of RA in females after menopause may in
part be due to a loss of TH2 protection after the drop in estrogen
levels [159]. Therefore, most animal models support the concept
that in patients with RA, TH2 responses seem to have a regulatory
function in disease.3. CD8+ T cells
CD8+ T cells have been shown to be crucial in the onset of sev-
eral experimental autoimmune disease models such as diabetes,
multiple sclerosis and myasthenia gravis [160–162]. The impor-
tance of CD8+ T cells in RA has been challenged with animal models
which reveal controversial roles for CD8+ T cells in disease induc-
tion or protection. Depletion of CD8+ T cells in the aforementioned
SCWmodel in rats lead to earlier disease onset and enhanced chro-
nicity [163]. On the other hand, studies using the CIA model in
B10.Q mice deﬁcient in CD8+ T cells showed no effect on disease
induction or severity [164], implicating that CD8+ T cells are not
important for pathogenesis. However, when mice were pre-
immunised with CII, the CD8+ T cells affected disease only when
they have been depleted two weeks after pre-immunisation, but
not at the same time [15]. This indicates that CD8+ T cells may
be important in the effector phase of disease but are dispensable
for its initiation. In addition, it has been suggested that the ability
of DBA/1 mice to develop arthritis in the absence of CD4 is due to
CD8+ T cells [13]. In the same study, the lack of CD8 in mice was
able to reduce disease incidence but had no effect on disease
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to disease induction after a boost post disease remission [13].
These two studies clearly outline the controversial and unclear role
that CD8+ T cells play in disease induction, and perhaps the effec-
tor-memory response associated with it, but they both support the
role of CD8+ T cells in regulating a primed immune response.
CD8+ mAb treatment of established AIA had no effect on disease,
and transfer of CD8+ T cells from arthritic rats into DA recipients
failed to establish disease [18,49]. Conversely, the spontaneous
development of disease in K/BN mice improved within 5 days
of CD8 depletion [165]. In PGIA, depletion of CD8+ cells prevented
disease transfer into irradiated recipient mice prevented disease
[59]. On the other hand, the depletion of CD8+ cells in immunised
mice exacerbated arthritis progression [60]. This may implicate
that in PGIA, CD8+ T cells are pathogenic in the pre-clinical stages
of disease but play a regulatory/protective role in established
arthritis.
Very little is known about the role of CD8+ in patients with RA,
although there is suggestion that CD8+ T cells are suppressive in RA
[166]. This was based on studies using human RA synovial tissues
grafted on SCID mice. The ability of CD8+ T cells to produce large
amounts of IFN-c may explain some of its regulatory mechanisms
via the ability of this cytokine to induce indoleamine 2,3-dioxygen-
ase (IDO). IDO catabolizes tryptophan into its catabolites such as
kynurenine, which exert immunosuppressive effects by suppress-
ing effector CD4+ T cell, inducing T cell apoptosis and enhancing
Treg functions [167]. Indeed, we have shown in the CIA model that
mice lacking IDO have exacerbated disease with a higher incidence
[168].4. Clinical implications
One of the major breakthroughs in the treatment of RA and
other inﬂammatory diseases such as Crohn’s disease and psoriasis
is anti-TNF therapy. Although macrophages and monocytes are be-
lieved to be the major producers of TNF-a in RA, T cells are abun-
dant in RA synovium and both CD4+ and CD8+ T cells are able to
produce large amounts of TNF-a as well as TNF-b (lymphotoxin);
the latter is only produced by T cells. While most anti-TNF thera-
pies target TNF-a, etanercept is able to neutralise both TNF-a
and TNF-b. Most biologics used for the treatment of RA, including
tocilizumab (anti IL-6R) and anakinra (IL-1Ra), do not speciﬁcally
target T cells, suggesting that T cell-targeted therapies may not
be necessary for disease amelioration. However, IL-6 is necessary
for TH17 development and IL-1 is reported to be necessary for
the early differentiation of TH17 cells [169]. This is exempliﬁed
by the fact that mice deﬁcient in IL-1Ra spontaneously develop
arthritis an IL-17-dependent manner [91]. In the CIA model, block-
ade of IL-6R suppresses disease and TH17 responses [170]. There-
fore, it would be interesting to assess whether anakinra or
tocilizumab-treated patients have reduced TH17 responses. Addi-
tionally, TNF-a induces the production of IL-1 and IL-6, therefore
indirectly affecting the TH17 population. IL-17A and F are both ex-
pressed in RA synovium and patients with RA have higher circulat-
ing numbers of TH17 cells [171,172]. As discussed above, animal
models of RA strongly suggest that the IL-17/TH17 pathway is an
important target. Indeed, anti-IL-17 therapy is now in phase III
clinical trials. In a small cohort, there is a suggestion that blockade
of IL-17 is effective, though not as much as TNF [173].
Our understanding of the contribution of IFN-c/TH1 to RA path-
ogenesis has not been made very clear from animal models be-
cause of opposing results. What seems to be clear is that IFN-c
may be important in the initiation of disease, and there is more evi-
dence that mice lacking IFN-c or its receptor have exacerbated dis-
ease. Indeed, in agreement with results from animal models, it isnot clear whether recombinant IFN-c administration is effective
in patients with RA. In one study with 197 patients, it was shown
that recombinant IFN-c had no greater effect than a placebo [174],
whereas in another study it was shown that IFN-c markedly re-
lieved disease symptoms [175]. In the CIA model, IFN-c seems to
be important in the induction of Treg [119]. Indeed, IFN-c is able
to increase foxp3 expression in the EAE model of MS [176]. There-
fore, administration of IFN-cmay ameliorate disease by increasing
Treg numbers or activity.5. Concluding remarks
Animal models of arthritis such as CIA have proved to be very
useful in the validation of therapeutic targets for RA, such as
TNF. More recently, transgenic and knockout strains of mice have
also enabled important advances and have led to a greater appre-
ciation of the complex and sometimes contradictory roles of cyto-
kines, in particular IFN-c, in disease pathogenesis. One mechanism
by which IFN-c acts is by suppressing the production of IL-17,
which is emerging as a key pathogenic cytokine, at least in animal
models [72,75,92,177]. However, caution is required in the extrap-
olation of these ﬁndings to man. For example, the protective effect
of IFN-c in CIA was found to be dependent on the presence of the
mycobacterial component of CFA and IFN-c was found to promote
arthritis in the absence of mycobacteria [178]. Nevertheless, data is
emerging of a protective role for IFN-c as patients presenting with
early resolving synovitis exhibited elevated levels of IFN-c com-
pared to patients which went on to develop full-blown RA [22].
The more recently described spontaneous models which are not
dependent on conventional adjuvants are proving to be highly
informative in elucidating pathogenetic mechanisms. For example,
the KxB/Nmodel has taught us that arthritis can occur as a result of
autoantibodies to an antigen (GPI) that is not joint-speciﬁc. In con-
trast, the SKG model has taught us that autoimmunity can arise
from a reduced, rather than increased, level of TCR signalling and
this is in accord with the reduced level of T cell activity observed
in RA [179]. The SKG mouse strain has also highlighted the impor-
tance of the interaction between the innate and adaptive immune
responses in triggering onset of disease and this may have impor-
tant implications for our understanding of human autoimmunity.
Animal models have also enabled us to understand the com-
plexity of the immune system in general, and the interplay be-
tween different effector T cells in disease pathogenesis in
speciﬁc. It is clear that certain T cell subtypes and their associated
cytokines are able to promote or negate others. For example, both
IFN-c and IL-4 are able to inhibit IL-17/TH17 in the AIA, SKG, CIA,
and PGIA models [72,75,92,100]. In contrast, IL-23, which is neces-
sary for the proliferation of TH17 cells, inhibits foxp3 and T bet, the
transcription factors for Treg and TH1 cells, respectively [104].
Although initially observed in patients with Crohn’s disease
[180], it is noteworthy that both human and mouse effector T cells
seem to possess a certain degree of plasticity. TH17 cells are able to
convert into TH1 cells, and CD4+ cells expressing both cytokines
have been characterised [181]. Therefore, cross-talk between effec-
tor T cells may be necessary to ﬁne-tune T cell lineage commit-
ment to control disease in its pre-clinical stage, where TH1 cells
seem to be pathogenic, or after disease onset, where TH17 cells
seem to be more pathogenic and TH1 cells seem to be protective.
Effector T cell plasticity in animal models of RA is something that
is worthy of investigation.
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